CELEX: 62013CA0310
Language: en
Date: 2014-11-20 00:00:00
Title: Case C-310/13: Judgment of the Court (Fourth Chamber) of 20 November 2014 (request for a preliminary ruling from the Bundesgerichtshof — Germany) — Novo Nordisk Pharma GmbH v S. (Reference for a preliminary ruling — Directive 85/374/EEC — Consumer protection — Liability for defective products — Material scope of the directive — Special liability system existing on the date of notification of that directive — Permissibility of a national liability system enabling information on the adverse effects of pharmaceutical products to be obtained)

26.1.2015   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 26/5
            
         Judgment of the Court (Fourth Chamber) of 20 November 2014 (request for a preliminary ruling from the Bundesgerichtshof — Germany) — Novo Nordisk Pharma GmbH v S.
   (Case C-310/13) (1)
   
   ((Reference for a preliminary ruling - Directive 85/374/EEC - Consumer protection - Liability for defective products - Material scope of the directive - Special liability system existing on the date of notification of that directive - Permissibility of a national liability system enabling information on the adverse effects of pharmaceutical products to be obtained))
   (2015/C 026/05)
   Language of the case: German
   
      Referring court
   
   Bundesgerichtshof
   
      Parties to the main proceedings
   
   
      Applicant: Novo Nordisk Pharma GmbH
   
      Defendant: S.
   
      Operative part of the judgment
   
   Council Directive 85/374/EEC of 25 July 1985 on the approximation of the laws, regulations and administrative provisions of the Member States concerning liability for defective products, as amended by Directive 1999/34/EC of the European Parliament and of the Council of 10 May 1999, must be interpreted as not precluding national legislation — such as that at issue in the main proceedings, establishing a special liability system for the purposes of Article 13 of that directive — under which, in consequence of an amendment to that legislation made after the directive had been notified to the Member State concerned, the consumer has the right to require the manufacturer of the medicinal product to provide him with information on the adverse effects of that product.
   
      (1)  OJ C 260, 7.9.2013.